Bladder Cancer Clinical Trial
— TPC-RCTOfficial title:
Trimodal Prehabilitation for Cystectomy Patients to Enhance Post-operative Care: A Randomized Control Trial
Trimodal prehabilitation is a preoperative three-tiered (trimodal) approach to optimizing
physical and mental health. It has been found to successfully improve functional recovery in
patients undergoing colorectal surgery following an evidence-based enhanced-recovery pathway
(ERP). It is unknown whether the same program is effective in patients undergoing a similar
surgery for bladder cancer (radical cystectomy).
Objective: To evaluate the appropriateness of a standardized prehabilitation program for
implementation into an enhanced recovery pathway for cystectomy patients and determine
whether prehabilitation facilitates earlier recovery of functional capacity.
Hypothesis: Prehabilitation will ultimately improve recovery of functional capacity, clinical
and patient-centered outcomes in patients undergoing radical cystectomy for bladder cancer.
Design: Participants will follow an 8-week trimodal prehabilitation program consisting of
exercise therapy combined with nutritional counseling, protein supplementation, and
psychological care; they will be compared to a cohort of participants following ERP care
alone.
Conclusion: The proposal will provide insight into the feasibility and effectiveness of
trimodal prehabilitation for radical cystectomy patients and may ultimately lead to improved
clinical outcomes and reduced morbidity.
Status | Not yet recruiting |
Enrollment | 50 |
Est. completion date | July 15, 2019 |
Est. primary completion date | January 15, 2019 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: 1. Male or female = 18 years of age at time of consent for surgery. 2. Documentation of bladder cancer diagnosis as evidenced by diagnostic imaging and biopsy. 3. May or may not receive adjuvant therapy. 4. Written informed consent obtained from subject Exclusion Criteria: 1. Presence of a condition or abnormality that in the opinion of the investigator would compromise the safety of the patient or adherence to the program. This includes: 1. American Society of Anesthesiologists (ASA) health class status 4-5; 2. Co-morbid medical, physical, and/or mental conditions including dementia, disabling orthopedic and neuromuscular disease, psychosis; 3. Severe cardiac abnormalities, end-stage organ disease, sepsis, or morbid obesity (BMI greater than 35); 2. Undergoing radical cystectomy for a reason other than bladder cancer. 3. Poor comprehension of English or French 4. Screened by Total Cardiology staff and determined to be inappropriate for prehabilitation at their facility. |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Jason Martyn | Alberta Health Services, Physiotherapy Alberta - College + Association, University of Alberta, University of Calgary |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Length of hospital stay (LOS) | Length of stay in the hospital starting from post-operative day #0 and terminating when the participant is discharged from the hospital. | Collected at the finale of participant-involvement (20-weeks) | |
Other | 30 day readmission rate | Number of participants re-admitted to hospital within 30 days of discharge as a percentage of the total number of participants involved in the study. | Collected at the finale of participant-involvement (20-weeks) | |
Other | Clavien-Dindo classification of Surgical Complications | A classification scheme that objectively grades surgical complications using a descriptive grading system. | Collected at the finale of participant-involvement (20-weeks) | |
Primary | 6-minute walk test (6MWT) | The 6MWT is a sub-maximal exercise test used to assess aerobic capacity and endurance. The distance covered over a time of 6 minutes is used as the outcome by which to compare changes in performance capacity. | Multiple time-points over 20-weeks | |
Secondary | 10-meter walk test (10mWT) | The 10 Metre Walk Test is a performance measure used to assess walking speed in metres per second over a short distance. It can be employed to determine functional mobility, gait, and vestibular function. | Multiple time-points over 20-weeks | |
Secondary | 30s sit-to-stand test (30CST) | The 30CST is a measurement that assesses functional lower extremity strength in older adults. It is part of the Fullerton Functional Fitness Test Battery. This test was developed to overcome the floor effect of the 5 or 10 repetition sit to stand test in older adults. | Multiple time-points over 20-weeks | |
Secondary | Hand-grip dynamometry | A quantitative and objective measure of isometric muscular strength of the hand and forearm, predictive of overall upper-extremity function. | Multiple time-points over 20-weeks | |
Secondary | Functional Assessment of Cancer Therapy for Bladder Cancer (FACT-Bl)Questionnaire | A reliable and valid questionnaire that comprehensively assesses quality of life concerns pertinent to bladder cancer patients. | Collected at beginning and end of 20-week participant involvement period | |
Secondary | EuroQOL five dimensions (EQ-5D) Questionnaire | A short, generic quality of life questionnaire | Collected at beginning and end of 20-week participant involvement period | |
Secondary | Godin Leisure Time Exercise Questionnaire | A short questionnaire on self-reported physical activity. | Collected at beginning and end of 20-week participant involvement period |
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT06034015 -
A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses of APL-1501 Extended Release (ER) Capsules Compared to APL-1202 Immediate Release (IR) Tablets in Healthy Volunteers
|
Phase 1 | |
Recruiting |
NCT04235764 -
En-bloc Transurethral Resection of Bladder Tumor (En-bloc TURBT) Specimens Using a Redesigned Surgical Resectoscope Device
|
||
Completed |
NCT02371447 -
VPM1002BC in Recurrent Non-muscle Invasive Bladder Cancer
|
Phase 1/Phase 2 | |
Recruiting |
NCT04081246 -
Transurethral Modified En Bloc Resection For Large Bladder Tumours.
|
N/A | |
Recruiting |
NCT06059547 -
Neoadjuvant Immunotherapy in Combination With the Anti-GDF-15 Antibody Visugromab (CTL-002) for Treatment of Muscle Invasive Bladder Cancer
|
Phase 2 | |
Terminated |
NCT04779489 -
Checkpoint Inhibitor and Radiation Therapy in Bulky, Node-Positive Bladder Cancer
|
N/A | |
Not yet recruiting |
NCT04493489 -
Propranolol Adjuvant Treatment of Bladder Cancer
|
Phase 2 | |
Completed |
NCT03520231 -
Study Comparing Denosumab With Standard Treatment in Urothelial Cancer Patients With Bone Metastases
|
Phase 2 | |
Recruiting |
NCT04537221 -
Nordic Cystectomy Study III - Transfusion
|
||
Withdrawn |
NCT03007771 -
Magnetic Resonance-guided High-Intensity Focused Ultrasound (MR-HIFU) Used for Mild Hyperthermia
|
Phase 1 | |
Completed |
NCT01955408 -
Severity of Overactive Bladder Symptoms in Patients After Synergo Treatment
|
N/A | |
Completed |
NCT04487457 -
Prospective Study to Evaluate the Blood Kinetics of Immune Cells and Immunosuppressive Cytokines After Exposure to an Immunity Checkpoint Inhibitor (ICI): Study of the Impact of Chemotherapy
|
||
Active, not recruiting |
NCT04383210 -
Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors
|
Phase 2 | |
Recruiting |
NCT05562791 -
A Study of 68Gallium PSMA-PET/CT Scans in People With Bladder Cancer
|
Phase 1 | |
Completed |
NCT00199849 -
NY-ESO-1 Plasmid DNA (pPJV7611) Cancer Vaccine
|
Phase 1 | |
Completed |
NCT02781428 -
To Detect the Sensitivity of the UroMark Assay
|
||
Recruiting |
NCT04738630 -
Study of HX008 for the Treatment of BCG-Unresponsive Non-muscle Invasive Bladder Cancer
|
Phase 2 | |
Completed |
NCT03980041 -
Study to Evaluate the Efficacy/Safety of IPI-549 in Combination With Nivolumab in Patients With Advanced Urothelial Carcinoma (MARIO-275)
|
Phase 2 | |
Active, not recruiting |
NCT03978624 -
Window of Opportunity Study of Pembrolizumab Alone and in Combinations in Bladder Cancer
|
Phase 2 | |
Completed |
NCT04534309 -
Behavioral Weight Loss Program for Cancer Survivors in Maryland
|
N/A |